首页|2017-2021年广元市HIV-1病毒学抑制失败感染者耐药情况分析

2017-2021年广元市HIV-1病毒学抑制失败感染者耐药情况分析

扫码查看
目的 分析广元市人类免疫缺陷病毒1型(Human Immunodeficiency Virus-1,HIV-1)感染者抗病毒治疗(Antiretroviral Therapy,ART)失败的耐药情况,为提高治疗成功率提供科学依据.方法 对2017-2021年广元市HIV-1 ART失败者治疗半年以上的血浆样本进行耐药检测和亚型分析,采用x2检验或Fisher精确检验进行率的比较,以P<0.05为差异有统计学意义.结果 2017-2021年广元市HIV-1病毒学抑制失败感染者有332例,耐药率为47.3%,对核苷类反转录酶抑制剂(Nucleoside Reverse Transcriptase Inhibitors,NRTIs)、非核苷类反转录酶抑制剂(Non-Nucleoside Reverse Transcriptase Inhibitors,NNRTIs)和蛋白酶类抑制剂(Protease Inhibitors,PIs)3类药物的耐药率分别为25.7%、42.1%和2.4%,差异有统计学意义(x2=129.8,P<0.001).NRTIs药物中,阿巴卡韦(ABC)耐药率最高(23.6%),M184耐药突变位点最常见(42.8%);NNRTIs药物中,依非韦伦(EFV)和奈韦拉平(NVP)耐药率一致且耐药率高达35.3%,K103耐药突变位点最常见(59.4%);PIs药物中,替拉那韦(TPV/r)耐药率最高为1.7%,Q58耐药突变位点最常见(2.9%).基因亚型以重组型(Circulating Recombinant Form,CRF)01_AE亚型(40.8%)和CRF07_BC 亚型(39.7%)为主,但CRF85_BC亚型和A亚型耐药率最高(100%),CRF55_01B亚型次之(80.0%).结论 2017-2021年广元市抗病毒治疗管理工作取得一定成效,但依然存在多种耐药毒株,且耐药基因突变位点复杂,需继续加强耐药监测及规范用药,进一步提升抗病毒治疗质量.
Analysis of drug resistance in HIV-1 infected patients with failed virological inhibition in Guangyuan City from 2017 to 2021
Objective To analyze the drug resistance of human immunodeficiency virus-1(HIV-1)infected patients with failed antiretroviral therapy(ART)in Guangyuan City,and to provide scientific basis for improving the success rate of treatment.Methods Plasma samples from HIV-1 ART failures treated for more than six months in Guangyuan City from 2017 to 2021 were analyzed for drug resistance detection and subtypes.Rates were compared by Chi-square test or Fisher's exact test,and differences were considered statistically significant with P<0.05.Results There were 332 cases of HIV-1 virological suppression failure infections in Guangyuan City from 2017 to 2021,with a drug resistance rate of 47.3%.Drug resistance rates to nucleoside reverse transcriptase inhibitors(NRTIs),non-nucleoside reverse transcriptase inhibitors(NNRTIs)and protease inhibitors(PIs)were 25.7%,42.1%and 2.4%,respectively,and the difference was statistically significant(x2=129.8,P<0.001).Among the NRTIs,abacavir(ABC)had the highest resistance rate(23.6%),and M184 resistance mutation site was the most common(42.8%).Among the NNRTIs,efavirenz(EFV)and nevirapine(NVP)had consistent and high resistance rates of 35.3%,and K103 resistance mutation site was the most common(59.4%).Among the PIs,the highest resistance rate was 1.7%for tiranavir(TPV/r),and Q58 resistance mutation site was the most common(2.9%).Genetic subtypes were dominated by circulating recombinant form(CRF)01_AE subtype(40.8%)and CRF07_BC subtype(39.7%).However,CRF85_BC and A subtypes had the highest resistance rate(100%),followed by CRF55_01B subtype(80.0%).Conclusions Antiviral treatment management work in Guangyuan City had achieved a certain success from 2017 to 2021.However,there are still multiple drug-resistant strains and complex drug-resistant gene mutation sites.Drug resistance monitoring and standardized drug use should be strengthened and the quality of antiviral treatment should be improved.

HIV-1antiretroviral therapydrug resistancesubtypes

熊丽、郜敏、李玲、侯雪芹、朱俊

展开 >

广元市疾病预防控制中心,四川 广元 628017

四川省疾病预防控制中心,成都 610041

HIV-1 抗病毒治疗 耐药 亚型

2024

预防医学情报杂志
中华预防医学会,四川省疾病预防控制中心

预防医学情报杂志

CSTPCD
影响因子:0.681
ISSN:1006-4028
年,卷(期):2024.40(4)
  • 16